Absci Corp (ABSI) is a leading U.S.-based life-sciences company pioneering innovative drug discovery and bio-manufacturing technologies. This pioneering company combines synthetic biology and computational biology to transform the drug discovery and manufacturing processes, primarily in the therapeutic areas of oncology, neurology, and immunology.
Founded in 2011 and headquartered in Vancouver, Washington, Absci Corp is deeply committed to reinventing the bio-pharmaceutical industry through its integrated, multiscale, and multidisciplinary approach to therapeutic development. This approach enables the company to design, build, and test a wide range of biologics, including proteins, therapeutic antibodies, and next-generation biologics, thereby streamlining the drug development process and reducing the time to market.
With a market capitalization of over $2 billion, Absci Corp debuted on the NASDAQ in July 2021, making an impressive splash in the high-impact biotechnology world. The company focuses on the lucrative pharmaceutical market which is expected to reach more than $1.5 trillion by 2023, proving the potential of their industry-disruptive innovations.
Absci's flagship technology platform, SoluPro™, is a proprietary protein-expression system that allows the production of complex proteins and biotherapeutics. Used in combination with their drug discovery platform, the system allows for the fast and efficient discovery of drug candidates. E. coli-based protein production, contrary to mammalian cells, enables higher yields, faster results and less investment.
The company also boasts of other platforms such as the Integrated Drug Creation Platform, which merges the capabilities of its drug discovery, cell line development, and bio-manufacturing platforms, as well as Protera, a computer-aided drug design (CADD) technology.
Absci Corp's innovative technologies are backed by partnerships with leading pharmaceutical companies like Merck, Genentech, and Eli Lilly. Its business model enables it to generate revenue through platform technology licensing, research collaboration agreements, and milestone and royalty payments based on partner development progress.
Absci’s acclaimed innovations, collaborative capabilities, and their commitment to accelerating the drug discovery process make them a key player in the biopharmaceutical industry. With a promising future, Absci Corp holds the potential to be a game-changer in the field of drug development, revolutionizing not only the process of discovery but also the accessibility of necessary, life-transforming therapeutics.